Aquestive Shares Surge 39% After FDA CRL, $12 Analyst Target Set
On Feb. 2, New Street set a $12 target on Aquestive, implying 193% upside from $4.10 after shares jumped 38.98% following an FDA CRL on Anaphylm. The CRL cited human factors issues in pouch opening, forcing AQST to revise packaging, initiate studies and resubmit in Q3 2026.
1. FDA Complete Response Letter Delays Anaphylm Approval
Aquestive Therapeutics received a Complete Response Letter from the U.S. Food and Drug Administration for its Anaphylm (dibutepinephrine) Sublingual Film, citing deficiencies in the human factors validation study related to pouch opening and film placement. The CRL precludes discussion of final labeling and post-marketing commitments until these issues are resolved. No chemistry, manufacturing or controls (CMC) concerns were noted, and comparability data submitted—such as bracketing, repeat-dose and sustainability studies—remained unchallenged by the agency.
2. Remediation Plan and Regulatory Timeline
In response, the company has redesigned the pouch, updated instructions for use, revised carton labeling and plans to conduct a fresh human factors validation study in parallel with a supporting pharmacokinetics trial requested by FDA clinical pharmacology. Aquestive projects completion of both studies and resubmission of the NDA in early third quarter 2026, with a request for an expedited review. Concurrently, management intends to file marketing applications in Europe and Canada in the second half of 2026, and anticipates feedback from the U.K. Medicines and Healthcare Products Regulatory Agency in the first quarter of 2026.
3. Analyst Ratings and Potential Upside
Several Wall Street firms have maintained bullish ratings despite the CRL setback. New Street Research reiterated a price target of twelve dollars, implying nearly two-times upside from current levels, while Oppenheimer continues to rate the stock as Outperform. Analyst expectations center on an approval decision in the first half of 2027, driven by rapid completion of the human factors and PK studies and the company’s strategy to address FDA feedback efficiently.
4. Market Position and Financial Resilience
Aquestive operates in the oral film-based drug delivery space, competing with established players such as Teva Pharmaceuticals and Viatris. The company’s market capitalization stands at roughly five hundred million dollars, with average daily trading volume exceeding sixty million shares on the NASDAQ. Management underscores a strong cash runway, supported by existing revenues from partnered products, which should fund the Anaphylm remediation program and global filings without immediate need for additional equity financing.